DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Role of Activin A in Immune Response to Breast Cancer
Annual rept. 15 Nov 2013-14 Nov 2014
NEW YORK UNIV NY
Pagination or Media Count:
In recent years, progress has been made in the development of immune-based therapy for cancer. Conceptually, these treatment strategies have the potential of harnessing the immune system to combat and eliminate cancer cells. One major obstacle to the success of immunotherapy in both human and animal studies is the development of immunologic tolerance in tumor-bearing hosts. Therefore, the immune system fails to recognize cancer cells as dangerous and actively suppresses antitumor immune responses. Identification of the underlying mechanisms and the critical players that drive tolerance to the tumor is critical to improve the therapeutic efficacy of immunotherapy. Recent data indicate that activin A, a small protein secreted by some immune cells and by breast cancer cells has immune regulatory functions that may play a key role in promoting escape of tumors from immune control. The proposed studies will test the hypothesis that activin A secreted by breast cancer cells plays a key role in suppressing antitumor immunity. The goals are to demonstrate the role of activin A produced by breast cancer cells in tumor growth and metastasis, and the potential therapeutic benefit of blocking activin A to increase the response to radiotherapy.
APPROVED FOR PUBLIC RELEASE